Clinical Trial

Study of IMC-P115C in Advanced PRAME-Positive Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-03.
Trial Details
NCT Number NCT07156136
Lead Sponsor Immunocore Ltd
Conditions PRAME Positive, Cancer, HLA-A*02:01-positive
Enrollment 140 participants
Start Date 2024-11-07
Primary Completion 2027-09-30 (estimated)
Study Completion 2029-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-25